老年房颤合并冠心病的抗栓方案及再住院原因分析

doi:10.3969/j.issn.1003-9198.2021.04.007

摘要/Abstract

摘要： 目的评价老年心房颤动(房颤)合并冠心病病人的抗栓治疗方案,并分析主要心血管不良事件(MACE)的发生与再住院原因。方法选取本院2013～2014年976例房颤合并冠心病病人,分成急性冠脉综合征(ACS)和稳定型冠心病(SCAD)2组并随访3年。分析2组不同卒中栓塞和出血评分下抗栓药物的选择、MACE导致再住院的发生率。结果与ACS病人首选口服双联抗血小板药物(DAPT)相比,SCAD病人更倾向于抗凝治疗(华法林或达比加群酯),2组差异有统计学意义(P<0.05)。3年随访期间,ACS组481例,115次住院,再住院率为23.9%;而SCAD组495例,176次住院,再住院率为35.5%,差异有统计学意义(P<0.05)。室性心律失常、心力衰竭及ACS是SCAD组再住院的前3位原因。心肌梗死和心力衰竭是ACS组的主要再住院原因。结论 ACS合并房颤的病人主要接受DAPT治疗,而SCAD合并房颤的病人则主要行口服抗凝药物治疗。与ACS病人相比,SCAD病人有着更高的MACE发生率和再住院率。

关键词: 老年人, 房颤, 冠心病, 抗栓

Abstract: Objective To evaluate the antithrombotic therapy in the elderly patients with atrial fibrillation combined with coronary heart disease, and to analyze the main adverse cardiovascular events (MACE) and the reasons of rehospitalization. Methods A total of 976 patients with atrial fibrillation combined with coronary heart disease from January 2013 to December 2014 in our hospital were selected, and were divided into acute coronary syndrome (ACS) group and stable coronary heart disease (SCAD) group and were followed up for 3 years. The selection of antithrombotic drugs, the incidence rate of readmission due to MACE in the two groups were compared. Results The patients in ACS group preferred dual antiplatelet therapy (DAPT), while those in SCAD group more inclined to anticoagulant therapy, and there was a significant difference between the two groups (P<0. 05). In ACS group, the rate of readmission was 23. 9%, compared with 35. 5% in the SCAD group(P<0. 05). Ventricular arrhythmia, heart failure, and ACS were the top three reasons for readmission in SCAD group. Myocardial infarction and heart failure were the main reasons of ACS group readmission. Conclusions ACS patients with atrial fibrillation tend to choose DAPT treatment, while SCAD patients tend to take oral anticoagulation therapy. Compared with ACS patients, SCAD patients have a higher MACE rate and readmission rate.

Key words: aged, atrial fibrillation, coronary heart disease, antithrombotic

中图分类号:

R 541

吴军, 门琛, 王森, 庞斯斯, 王向明, 许迪, 郭妍. 老年房颤合并冠心病的抗栓方案及再住院原因分析[J]. 实用老年医学, 2021, 35(4): 345-349.

WU Jun, MEN Chen, WANG Sen, PANG Si-si, WANG Xiang-ming, XU Di, GUO Yan. Antithrombotic therapy and reason of readmission in elderly patients with atrial fibrillation combined with coronary heart disease[J]. Practical Geriatrics, 2021, 35(4): 345-349.

参考文献

[1] ICE D S, SHAPIRO T A, GNALL E M, et al. Unanswered questions in patients with concurrent atrial fibrillation and acute coronary syndrome[J]. Am J Cardiol, 2014, 113(5): 888-896.
[2] ROHLA M, VENNEKATE C K, TENTZERIS I, et al. Long-term mortality of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation for acute and stable coronary artery disease[J]. Int J Cardiol, 2015, 184: 108-114.
[3] European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, CAMM A J, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2010, 31(19): 2369-2429.
[4] KIRCHHOF P, AMMENTORP B, DARIUS H, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the Prevention oF thromboemolic events-European Registry in Atrial Fibrillation (PREFER in AF)[J]. Europace, 2014, 16(1): 6-14.
[5] MISCHKE K, KNACKSTEDT C, MARX N. Anticoagulant and antiplatelet therapy in patients with atrial fibrillation and coronary artery disease[J]. Thrombosis, 2012, 2012: 184573.
[6] DEWILDE W J, OIRBANS T, VERHEUGT F W, et al. WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial[J]. Lancet, 2013, 381(9872): 1107-1115.
[7] LAMBERTS M, GISLASON G H, OLESEN J B, et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention[J]. J Am Coll Cardiol, 2013, 62(11): 981-989.
[8] CHOI H I, AHN J M, KANG S H, et al. Prevalence, management, and long-term (6-year) outcomes of atrial fibrillation among patients receiving drug-eluting coronary stents[J]. JACC Cardiovasc Interv, 2017, 10(11): 1075-1085.
[9] JONES W S, MI X, PATEL M R, et al. Combined use of warfarin and oral P2Y12 inhibitors in patients with atrial fibrillation and acute coronary syndrome[J]. Clin Cardiol, 2014, 37(3): 152-159.

[1]	丛晓飞, 李铭麟, 石春来. 老年口腔衰弱与多重用药的关系及干预策略[J]. 实用老年医学, 2024, 38(9): 872-875.
[2]	李毛毛, 张飞, 沈鑫, 李洁华. 老年人口腔衰弱与跌倒关系的研究进展[J]. 实用老年医学, 2024, 38(9): 876-879.
[3]	张飞, 李毛毛, 李铭麟, 王佳贺. 老年人口腔衰弱与抑郁症的相关性研究进展[J]. 实用老年医学, 2024, 38(9): 884-888.
[4]	李江, 邱雁, 王婷, 王丹, 虞一帆, 濮玲丽, 卜玲. 老年肺腺癌病人术前全身免疫炎症指数/血清白蛋白与临床病理特征的相关性研究[J]. 实用老年医学, 2024, 38(9): 893-896.
[5]	戴静, 崔焱. 糖化血红蛋白变异性与老年2型糖尿病病人认知功能障碍的相关性分析[J]. 实用老年医学, 2024, 38(9): 931-935.
[6]	张星星, 张海洋, 何小菁, 鲁翔. 不同肥胖指标与老年人糖尿病患病风险的调查研究[J]. 实用老年医学, 2024, 38(9): 940-943.
[7]	倪红艳, 陈云, 张其兵, 马一鸣, 解成兰. 电针对老年病人下肢骨科手术围术期认知功能及炎症因子的影响[J]. 实用老年医学, 2024, 38(9): 944-947.
[8]	李晓敏, 李晓林, 栗杰, 吴蕾, 郝冉冉. 老年病人经肛双气囊小肠镜进镜效率及其影响因素研究[J]. 实用老年医学, 2024, 38(9): 958-961.
[9]	蔡荟萃, 陈燕, 王燕, 叶劲军, 朱钰颖. 多形式健康教育模式联合简易呼吸功能锻炼对老年肺癌放疗病人癌因性疲乏及遵医行为的影响[J]. 实用老年医学, 2024, 38(9): 968-972.
[10]	李湘, 栗萱, 田应选. 肺衰老与慢性呼吸系统疾病研究现状及进展[J]. 实用老年医学, 2024, 38(8): 761-765.
[11]	王小娇, 王宁, 崔宏, 叶童, 王晓明. 运动康复对老年轻中度慢性心力衰竭病人的疗效评价[J]. 实用老年医学, 2024, 38(8): 775-778.
[12]	郝世杰, 邹建鹏, 卫晨, 刘清江. 综合呼吸训练对老年帕金森病病人运动减少型构音障碍的影响[J]. 实用老年医学, 2024, 38(8): 783-787.
[13]	向超, 罗彩东. 心电图avL导联T波变化对老年冠心病病人冠脉狭窄程度的诊断价值[J]. 实用老年医学, 2024, 38(8): 788-791.
[14]	李慧颖, 蔡力力, 朱启伟. 血浆N末端脑钠肽前体对高龄左室肥厚病人预后的预测价值[J]. 实用老年医学, 2024, 38(8): 797-801.
[15]	王新平, 谢柏梅, 卫国, 叶晓莉, 赵亚芸, 谭小田. 老年特发性间质性肺炎病人血清S100A9及sCD163表达水平及临床意义[J]. 实用老年医学, 2024, 38(8): 802-807.